Rgenta Therapeutics secures FDA nod for IND application of RGT-61159, an oral RNA modulator intended to stop MYB production, targeting Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC).

Ryplazim was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021. This approval marked a significant milestone as Ryplazim is the first therapy approved for treating plasminogen deficiency type 1.

Avalo Therapeutics Reports IND Activation for AVTX-009, an anti-IL-1β Antibody, Aimed at Treating Hidradenitis Suppurativa.

Tembexa (brincidofovir) was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021.

uniQure Releases Promising Interim Results Showing Reduced Disease Progression in Phase I/II AMT-130 Trials for Huntington’s Disease.

Brexafemme (ibrexafungerp) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021.

The agreement specifies that the Phase 2 clinical trial will evaluate the effectiveness of PRT37890, a new and highly selective SMARCA2 degrader, and Merck's KEYTRUDA in treating cancers with SMARCA4 mutations.

Lybalvi, a combination of olanzapine and samidorphan, is an antipsychotic medication designed to treat specific mental health conditions in adults. Lybalvi was approved by the U.S. Food and Drug Administration (FDA) on May 28, 2021.

Kiniksa Pharmaceuticals International announced that it has begun enrolling participants for the Phase 2b clinical trial of abiprubart in Sjögren’s Disease.

Sotorasib, marketed under the brand name Lumakras, is a medication designed to treat non-small cell lung cancer (NSCLC). Sotorasib was granted FDA approval on May 28, 2021.

AEON Biopharma revealed their intention to proceed with a crucial clinical development trial in cervical dystonia for their main product, ABP-450 (prabotulinumtoxinA) injection.

Myfembree is a combination oral medication containing estradiol, norethindrone, and relugolix. Myfembree was approved by the FDA on May 26, 2021.